Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery

Recruiting now · Not applicable

Conditions studied: Glaucoma, Open-Angle, Cataract

In brief

This study is designed to determine how well patients with glaucoma can see following cataract surgery with a special type of lens called an extended-depth-of-focus (EDOF) lens. This lens is intended to reduced the patients need for glasses following cataract surgery. Patients will also undergo a minimally invasive type of glaucoma surgery using a special type of stent to reduce eye pressure, with the goal of better glaucoma control and the reduction in the need for medications to control eye pressure.

Key facts

Study ID: NCT05624398
Run by: Vold Vision P.L.L.C
People needed: 25
Starts: 2022-12-07
Expected to finish: 2025-05-01
Last updated by the study team: 2024-08-13

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female subjects 45 years of age or older
A visually significant age-related cataract in both eyes
Diagnosis of mild OAG
VF characteristics consistent with glaucoma with mean deviation not worse than -6.00 dB and without fixation threatening scotoma AND/OR with nerve abnormalities consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve fiber layer loss)
Medicated IOP ≤25 mmHg on 1-3 hypotensive medications
Glaucoma must be judged as stable by investigator based on review of subject medical records
Stable VF at least 1 year prior to surgery
Stable nerve fiber layer at least 1 year prior to surgery
IOP stable on current medication regimen at least 3 months prior to surgery
Shaffer grade of ≥ III in all angle quadrants
Potential of best corrected visual acuity at distance in the investigator's judgement of at least 0.1 logMAR (20/25) postoperatively
Able and willing to comply with follow up visits
Understands and signs the informed consent
Both eyes of the subject should undergo surgery within 21 days of each other to ensure adequate timing for final visit window of 90 days ± 21 days post operatively

You may not qualify if…

Previous incisional glaucoma surgery or cilio-ablative surgery
Prior laser trabeculoplasty within 90 days of surgery
Pseudoexfoliative, angle closure, uveitic, congenital, traumatic, angle recession, or neovascular glaucoma.
Moderate glaucoma with VF mean deviation between -6.00 dB and -12.00 dB
Severe and/or progressive glaucoma defined as
VF mean deviation worse than -12.00 dB
Consistent worsening of visual field on review of subject medical records
Consistent and progressive thinning of nerve fiber layer on review of subject medical records
Uncontrolled IOP on maximum glaucoma medications
Historically poor IOP control with medical therapy
Severe focal notching of the optic nerve rim
Expectation for future need of incisional glaucoma surgery
Ocular pathology or other medical condition which, in the investigator's judgment places the subject at increased risk of complications or significant vision loss during study period
Ocular pathology that in the investigator's judgment may impact visual acuity postoperatively, i.e., significant ocular surface disease, corneal scarring, blepharitis, epiretinal membrane, macular degeneration, history of significant ocular trauma with sequela, etc.
Pregnant or breastfeeding women
Prior refractive surgery e.g., LASIK, RK, PRK, etc.
Subjects with significant complications during surgical procedure e.g., broken capsule, Hydrus Microstent complication, will be exited from the trial
Subjects who experience visually significant complications related to the Hydrus Microstent during the study period will be exited from the trial

Where it is running

Vold Vision P.L.L.C. — Fayetteville, Arkansas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.